ProShares Ultra Silver ETF vs Becton Dickinson and Co — how do they compare? ProShares Ultra Silver ETF trades at $82.85, while Becton Dickinson and Co trades at $178.47 (market cap $49.41B). The key difference: Becton Dickinson and Co pays a 2.32% dividend while ProShares Ultra Silver ETF pays none, and Becton Dickinson and Co is trading nearer its 52-week high, ProShares Ultra Silver ETF nearer its low. Which is the better fit depends on your goals.
| AGQ | BDX | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $400.47 | $185.39 |
52-Week Low | $49.73 | $138.62 |
Market Cap | — | $49.41B |
Enterprise Value | — | $65.51B |
Dividend Yield | — | 2.32% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.
The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.
Trailing returns across standard periods
Latest headlines on both assets
AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.
Read more on AGQ →Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →